Human carbonic anhydrases (CA, EC, 4.2.1.1) IX and XII are overexpressed in cancer cells as adaptive response to hypoxia and acidic conditions characteristic of many tumors. In addition, hypoxia facilitates the activity of specific oxido-reductases that may be exploited to selectively activate bio-reductive prodrugs. Here, new selective CA IX/XII inhibitors, as analogues of the anti-tumor phase II drug SLC-0111 are described, namely ureido-substituted benzenesulfonamides appended with a nitro-aromatic moiety to yield an anti-proliferative action increased by hypoxia. These compounds were screened for the inhibition of the ubiquitous hCA I/II and the target hCA IX/XII. Six X-ray crystallographies with CA II and IX/mimic allowed for the rationalization of the compounds inhibitory activity. The effects of some such compounds on the viability of HT-29, MDA-MB-231 and PC-3 human cancer cell lines in both normoxic and hypoxic conditions were examined, providing the initiation towards the development of hypoxia-activated anti-tumor CAIs.

4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides selectively target the tumor-associated carbonic anhydrase isoforms IX and XII showing hypoxia-enhanced anti-proliferative profiles / Nocentini A, Trallori E, Singh S, Lomelino CL, Bartolucci G, Di Cesare Mannelli L, Ghelardini C, McKenna R, Gratteri P, Supuran CT. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0022-2623. - ELETTRONICO. - 61:(2018), pp. 10860-10874. [10.1021/acs.jmedchem.8b01504]

4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides selectively target the tumor-associated carbonic anhydrase isoforms IX and XII showing hypoxia-enhanced anti-proliferative profiles.

Nocentini A;Trallori E;Bartolucci G;Di Cesare Mannelli L;Ghelardini C;Gratteri P
;
Supuran CT
2018

Abstract

Human carbonic anhydrases (CA, EC, 4.2.1.1) IX and XII are overexpressed in cancer cells as adaptive response to hypoxia and acidic conditions characteristic of many tumors. In addition, hypoxia facilitates the activity of specific oxido-reductases that may be exploited to selectively activate bio-reductive prodrugs. Here, new selective CA IX/XII inhibitors, as analogues of the anti-tumor phase II drug SLC-0111 are described, namely ureido-substituted benzenesulfonamides appended with a nitro-aromatic moiety to yield an anti-proliferative action increased by hypoxia. These compounds were screened for the inhibition of the ubiquitous hCA I/II and the target hCA IX/XII. Six X-ray crystallographies with CA II and IX/mimic allowed for the rationalization of the compounds inhibitory activity. The effects of some such compounds on the viability of HT-29, MDA-MB-231 and PC-3 human cancer cell lines in both normoxic and hypoxic conditions were examined, providing the initiation towards the development of hypoxia-activated anti-tumor CAIs.
2018
61
10860
10874
Nocentini A, Trallori E, Singh S, Lomelino CL, Bartolucci G, Di Cesare Mannelli L, Ghelardini C, McKenna R, Gratteri P, Supuran CT
File in questo prodotto:
File Dimensione Formato  
91.Nocentini_JMedChem2018.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: DRM non definito
Dimensione 4.53 MB
Formato Adobe PDF
4.53 MB Adobe PDF   Richiedi una copia
Submitted_4Hydroxy_CAIX-XII.pdf

accesso aperto

Descrizione: versione submitted
Tipologia: Preprint (Submitted version)
Licenza: Open Access
Dimensione 684.63 kB
Formato Adobe PDF
684.63 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1142385
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 47
  • ???jsp.display-item.citation.isi??? 42
social impact